ZYNLONTA® (loncastuximab tesirine-lpyl)
Relapsed or Refractory Large B-cell Lymphoma (after ≥2 prior therapies)
Key Facts
About ADC Therapeutics
ADC Therapeutics is a Switzerland-based biopharmaceutical company dedicated to transforming cancer treatment through its focused portfolio of antibody-drug conjugates. The company has achieved commercial success with ZYNLONTA®, an FDA-approved anti-CD19 ADC for specific types of large B-cell lymphoma, and is actively pursuing label expansion for this product. Concurrently, ADC Therapeutics is advancing its pipeline, including a promising PSMA-targeting ADC for solid tumors, aiming to deliver more effective and targeted therapies for patients with difficult-to-treat cancers.
View full company profileAbout ADC Therapeutics
ADC Therapeutics is a Switzerland-based biopharmaceutical company dedicated to transforming cancer treatment through its focused portfolio of antibody-drug conjugates. The company has achieved commercial success with ZYNLONTA®, an FDA-approved anti-CD19 ADC for specific types of large B-cell lymphoma, and is actively pursuing label expansion for this product. Concurrently, ADC Therapeutics is advancing its pipeline, including a promising PSMA-targeting ADC for solid tumors, aiming to deliver more effective and targeted therapies for patients with difficult-to-treat cancers.
View full company profile